Results 171 to 180 of about 2,846 (197)

Does cilengitide deserve another chance?–Authors' reply

The Lancet Oncology, 2014
Stupp R, Picard M, Weller M
openaire   +5 more sources

ANTIVIRAL USE OF CILENGITIDE

2021
CICIN-SAIN LUKA, ESCHKE KATHRIN, KIM YEONSU   +2 more
openaire   +1 more source

In-vitro and in-vivo effects of Cilengitide in Glioblastoma models

Klinische Pädiatrie, 2013
J Schubert, C Mullins, S van Gool, L Vandenberk, M Linnebacher, CF Classen   +5 more
openaire   +1 more source

[Cilengitide].

Nihon rinsho. Japanese journal of clinical medicine, 2019
Kazuhiko, Kurozumi, Joji, Ishida, Tomotsugu, Ichikawa, Isao, Date   +3 more
openaire   +1 more source

Cilengitide in glioblastoma: when did it fail?

The Lancet Oncology, 2014
openaire   +2 more sources

Combination effect of cilengitide derivatives with gefitinib on TGF-β1-induced epithelial-to-mesenchymal transition in human non-small cell lung cancer cells

Bulletin of the Korean Chemical Society, 2022
Jiyeon Kim
exaly  

Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors

Annals of Oncology, 2007
S G Eckhardt, L Gore, S G Eckhardt
exaly  

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)

Annals of Oncology, 2015
Johan Vansteenkiste, Kenneth J O'Byrne, E Goekkurt   +2 more
exaly  

Metabolism and disposition of the αv-integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans

Journal of Clinical Pharmacology, 2015
Oliver von Richter, PhD FCP, Andreas Johne   +1 more
exaly  

What Role Should Cilengitide Have in the Treatment of Glioblastoma?

Journal of Clinical Oncology, 2010
openaire   +2 more sources